Nektar Therapeutics (NKTR) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $55.50: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 13.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Negative price momentum.
Nektar Therapeutics is a clinical-stage biopharma focused on immunomodulatory drug candidates, primarily rezpegaldesleukin (atopic dermatitis, alopecia areata, type 1 diabetes) and NKTR-255 (oncology). The company generates no product revenue; it funds operations through equity... Read more
Sell if holding. Engine safety override at $55.50: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 13.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.6/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 58d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent developments
updated 2026-06-09Recent Developments — Nektar Therapeutics
Latest news
- NEWS Wedbush Maintains Neutral on Nektar Therapeutics, Lowers Price Target to $80 — benzinga May 11, 2026 neutral
- NEWS Nektar Therapeutics Says Sandra Gardiner To Retire As Interim CFO, Appoints Linda Rubinstein As Interim CFO, Effective M — benzinga May 8, 2026 neutral
- NEWS Nektar Therapeutics To Offer Up To $150M In Common Stock Via Equity Distribution Agreement — benzinga May 8, 2026 neutral
- NEWS Piper Sandler Maintains Overweight on Nektar Therapeutics, Raises Price Target to $192 — benzinga May 8, 2026 positive
- NEWS Nektar Therapeutics Q1 EPS $(1.82) Misses $(1.62) Estimate, Sales $10.860M Beat $10.636M Estimate — benzinga May 7, 2026 neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinerezpegaldesleukin10-K Item 1A: 'We are highly dependent on the success of drug candidates, particularly rezpegaldesleukin (previously referred to as NKTR-358). If these drug candidates fail in clinical development our business will be significantly harmed.'
Material Events(8-K, last 90d)
- 2026-05-08Item 1.01LOWNektar entered Equity Distribution Agreement with Guggenheim Securities and H.C. Wainwright for at-the-market offering of up to $150M in common stock. Company is not obligated to make any sales.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Unprofitable operations — net margin -284.2%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $55.50: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 13.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $52.51. Score 4.6/10, moderate confidence.
Take-profit target: $133.33 (+137.1% upside). Prior stop was $52.51. Stop-loss: $52.51.
Concentration risk — Pipeline: rezpegaldesleukin; Quality below floor (3.9 < 4.0); Value-trap signals (2/5): Margin compression (op margin -12.4%), Material insider selling (119 sells, 0.25% of cap).
Nektar Therapeutics trades at a P/E of N/A (forward -4.5). TrendMatrix value score: 5.4/10. Verdict: Sell.
16 analysts cover NKTR with a consensus score of 4.3/5. Average price target: $153.
What does Nektar Therapeutics do?Nektar Therapeutics is a clinical-stage biopharma focused on immunomodulatory drug candidates, primarily...
Nektar Therapeutics is a clinical-stage biopharma focused on immunomodulatory drug candidates, primarily rezpegaldesleukin (atopic dermatitis, alopecia areata, type 1 diabetes) and NKTR-255 (oncology). The company generates no product revenue; it funds operations through equity and debt financings and had $245.8M in cash and marketable securities as of December 31, 2025. Rezpegaldesleukin's Phase 2b REZOLVE-AD trial met its primary endpoint in June 2025.